Literature DB >> 8765472

Tetrahydrocannabinol inhibition of macrophage nitric oxide production.

R G Coffey1, Y Yamamoto, E Snella, S Pross.   

Abstract

delta 9-Tetrahydrocannabinol (THC) inhibited nitric oxide (NO) production by mouse peritoneal macrophages activated by bacterial endotoxin lipopolysaccharide (LPS) and interferon-gamma (IFN)-gamma). Inhibition of NO production was noted at THC concentrations as low as 0.5 microgram/mL, and was nearly total at 7 micrograms/mL. Inhibition was greatest if THC was added 1-4 hr before induction of nitric oxide synthase (NOS) by LPS and IFN-gamma, and declined with time after addition of the inducing agents. This suggested that an early step such as NOS gene transcription or NOS synthesis, rather than NOS activity, was affected by THC. Steady-state levels of mRNA for NOS were not affected by THC. In contrast, protein synthesis was inhibited as indicated by immunoblotting. NOS activity was also decreased in the cytosol of cells pretreated with THC. Addition of excess cofactors did not restore activity. Inhibition of NO production was greater at low levels of IFN-gamma, indicating the ability of the cytokine to overcome inhibition. The effectiveness of various THC analogues, in decreasing order of potency, was delta 8-THC > delta 9-THC > cannabidiol > or = 11-OH-THC > cannabinol. The presumably inactive stereoisomer, (+)delta 9-THC, and the endogenous ligand for cannabinoid receptors, anandamide, were weakly inhibitory. Inhibition may be mediated by a process that depends partly on stereoselective receptors and partly on a nonselective process. LPS, IFN-gamma, hormone receptor agonists, and forskolin increased macrophage cyclic AMP levels. THC inhibited this increase, indicating functional cannabinoid receptors. Addition of 8-bromocyclic AMP increased NO 2-fold, and partially restored NO production that had been inhibited by THC. This occurred only under conditions of limited NOS induction, suggesting that the effect of THC on cyclic AMP was responsible for only a small portion of the inhibition of NO.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765472     DOI: 10.1016/0006-2952(96)00356-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  22 in total

1.  Potentiation of cytokine induced iNOS expression in the human intestinal epithelial cell line, DLD-1, by cyclic AMP.

Authors:  M Cavicchi; B J Whittle
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

Review 2.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

Review 3.  Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

Authors:  G A Cabral; L Griffin-Thomas
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-09       Impact factor: 2.895

4.  Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.

Authors:  D C Hammell; L P Zhang; F Ma; S M Abshire; S L McIlwrath; A L Stinchcomb; K N Westlund
Journal:  Eur J Pain       Date:  2015-10-30       Impact factor: 3.931

Review 5.  Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks.

Authors:  Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-08       Impact factor: 9.236

6.  Nitric oxide and macrophage antiviral extrinsic activity.

Authors:  F Benencia; M C Courreges
Journal:  Immunology       Date:  1999-11       Impact factor: 7.397

7.  The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.

Authors:  A M Malfait; R Gallily; P F Sumariwalla; A S Malik; E Andreakos; R Mechoulam; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 8.  Cannabinoids and neuroinflammation.

Authors:  Lisa Walter; Nephi Stella
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

9.  Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw.

Authors:  Barbara Costa; Mariapia Colleoni; Silvia Conti; Daniela Parolaro; Chiara Franke; Anna Elisa Trovato; Gabriella Giagnoni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-12       Impact factor: 3.000

10.  Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.

Authors:  Maria Teresa Cencioni; Valerio Chiurchiù; Giuseppina Catanzaro; Giovanna Borsellino; Giorgio Bernardi; Luca Battistini; Mauro Maccarrone
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.